- Report
- January 2026
- 197 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- September 2025
- 250 Pages
Global
From €3902EUR$4,490USD£3,396GBP
- Report
- February 2026
- 398 Pages
Global
From €5084EUR$5,850USD£4,425GBP
- Report
- February 2026
- 194 Pages
Global
From €5084EUR$5,850USD£4,425GBP
- Report
- September 2025
- 250 Pages
Global
From €3902EUR$4,490USD£3,396GBP
Ceftaroline is an antibiotic used to treat a variety of bacterial infections, including skin and soft tissue infections, community-acquired pneumonia, and complicated urinary tract infections. It is a cephalosporin antibiotic, which works by inhibiting the synthesis of bacterial cell walls. Ceftaroline is available in both intravenous and oral formulations, and is often used in combination with other antibiotics.
Ceftaroline is a relatively new antibiotic, and is increasingly being used in clinical practice due to its broad spectrum of activity and good safety profile. It is particularly useful in treating infections caused by multi-drug resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).
The ceftaroline market is highly competitive, with several major pharmaceutical companies offering the drug. These include Merck & Co., Pfizer, AstraZeneca, and Allergan. Show Less Read more